These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 19320532)

  • 1. Pharmacotherapy in paediatric obsessive-compulsive disorder: a naturalistic, retrospective study.
    Masi G; Millepiedi S; Perugi G; Pfanner C; Berloffa S; Pari C; Mucci M
    CNS Drugs; 2009; 23(3):241-52. PubMed ID: 19320532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bipolar co-morbidity in pediatric obsessive-compulsive disorder: clinical and treatment implications.
    Masi G; Perugi G; Millepiedi S; Toni C; Mucci M; Pfanner C; Berloffa S; Pari C; Akiskal HS
    J Child Adolesc Psychopharmacol; 2007 Aug; 17(4):475-86. PubMed ID: 17822342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A naturalistic study of referred children and adolescents with obsessive-compulsive disorder.
    Masi G; Millepiedi S; Mucci M; Bertini N; Milantoni L; Arcangeli F
    J Am Acad Child Adolesc Psychiatry; 2005 Jul; 44(7):673-81. PubMed ID: 15968236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aripiprazole augmentation in 39 adolescents with medication-resistant obsessive-compulsive disorder.
    Masi G; Pfanner C; Millepiedi S; Berloffa S
    J Clin Psychopharmacol; 2010 Dec; 30(6):688-93. PubMed ID: 21105283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical predictors of drug nonresponse in obsessive-compulsive disorder.
    Shetti CN; Reddy YC; Kandavel T; Kashyap K; Singisetti S; Hiremath AS; Siddequehusen MU; Raghunandanan S
    J Clin Psychiatry; 2005 Dec; 66(12):1517-23. PubMed ID: 16401151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
    Bloch MH; Landeros-Weisenberger A; Kelmendi B; Coric V; Bracken MB; Leckman JF
    Mol Psychiatry; 2006 Jul; 11(7):622-32. PubMed ID: 16585942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of comorbidity on treatment response to paroxetine in pediatric obsessive-compulsive disorder: is the use of exclusion criteria empirically supported in randomized clinical trials?
    Geller DA; Biederman J; Stewart SE; Mullin B; Farrell C; Wagner KD; Emslie G; Carpenter D
    J Child Adolesc Psychopharmacol; 2003; 13 Suppl 1():S19-29. PubMed ID: 12880497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder.
    McDougle CJ; Epperson CN; Pelton GH; Wasylink S; Price LH
    Arch Gen Psychiatry; 2000 Aug; 57(8):794-801. PubMed ID: 10920469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Systematic Review of Evidence-based Treatment Strategies for Obsessive- compulsive Disorder Resistant to first-line Pharmacotherapy.
    Albert U; Marazziti D; Di Salvo G; Solia F; Rosso G; Maina G
    Curr Med Chem; 2018; 25(41):5647-5661. PubMed ID: 29278206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secondary outcomes from the pediatric obsessive compulsive disorder treatment study II.
    Conelea CA; Selles RR; Benito KG; Walther MM; Machan JT; Garcia AM; Sapyta J; Morris S; Franklin M; Freeman JB
    J Psychiatr Res; 2017 Sep; 92():94-100. PubMed ID: 28412602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors.
    Denys D; de Geus F; van Megen HJ; Westenberg HG
    J Clin Psychiatry; 2004 Aug; 65(8):1040-8. PubMed ID: 15323587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Diversity of obsessive-compulsive disorder and pharmacotherapy associated with obsessive-compulsive spectrum disorders].
    Nakamae T
    Seishin Shinkeigaku Zasshi; 2011; 113(10):1016-25. PubMed ID: 22187889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serotonin reuptake inhibitor-cognitive behavioural therapy-second generation antipsychotic combination for severe treatment-resistant obsessive-compulsive disorder. A prospective observational study.
    Tundo A; Salvati L; Cieri L; Balestrini V; Di Spigno D; Orazi F; Iommi M; Necci R
    Int J Psychiatry Clin Pract; 2022 Nov; 26(4):395-400. PubMed ID: 35323098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A naturalistic exploratory study of the impact of demographic, phenotypic and comorbid features in pediatric obsessive-compulsive disorder.
    Masi G; Millepiedi S; Perugi G; Pfanner C; Berloffa S; Pari C; Mucci M; Akiskal HS
    Psychopathology; 2010; 43(2):69-78. PubMed ID: 20068377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Issues in the pharmacological treatment of obsessive-compulsive disorder.
    Math SB; Janardhan Reddy YC
    Int J Clin Pract; 2007 Jul; 61(7):1188-97. PubMed ID: 17511795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762].
    Carey PD; Vythilingum B; Seedat S; Muller JE; van Ameringen M; Stein DJ
    BMC Psychiatry; 2005 Jan; 5():5. PubMed ID: 15667657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of trauma and post-traumatic stress disorder on the treatment response of patients with obsessive-compulsive disorder.
    Shavitt RG; Valério C; Fossaluza V; da Silva EM; Cordeiro Q; Diniz JB; Belotto-Silva C; Cordioli AV; Mari J; Miguel EC
    Eur Arch Psychiatry Clin Neurosci; 2010 Mar; 260(2):91-9. PubMed ID: 20077119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial.
    Simpson HB; Foa EB; Liebowitz MR; Huppert JD; Cahill S; Maher MJ; McLean CP; Bender J; Marcus SM; Williams MT; Weaver J; Vermes D; Van Meter PE; Rodriguez CI; Powers M; Pinto A; Imms P; Hahn CG; Campeas R
    JAMA Psychiatry; 2013 Nov; 70(11):1190-9. PubMed ID: 24026523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder.
    Saxena S; Wang D; Bystritsky A; Baxter LR
    J Clin Psychiatry; 1996 Jul; 57(7):303-6. PubMed ID: 8666572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study.
    Li X; May RS; Tolbert LC; Jackson WT; Flournoy JM; Baxter LR
    J Clin Psychiatry; 2005 Jun; 66(6):736-43. PubMed ID: 15960567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.